PND95 EPTINEZUMAB DEMONSTRATED EARLY AND SUSTAINED REDUCTIONS IN HIT-6 TOTAL AND ITEM SCORES OVER TIME IN PATIENTS WITH CHRONIC MIGRAINE IN THE PROMISE-2 TRIAL